These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36926698)

  • 1. Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring.
    Kumar P; Vuyyuru SK; Das P; Kante B; Ranjan MK; Thomas DM; Mundhra S; Sahu P; Venigalla PM; Jain S; Goyal S; Golla R; Virmani S; Singh MK; Sachdeva K; Sharma R; Dash NR; Makharia G; Kedia S; Ahuja V
    Intest Res; 2023 Oct; 21(4):460-470. PubMed ID: 36926698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.
    Verstockt S; Verstockt B; Machiels K; Vancamelbeke M; Ferrante M; Cleynen I; De Hertogh G; Vermeire S
    Inflamm Bowel Dis; 2021 Oct; 27(10):1564-1575. PubMed ID: 33624092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment.
    Lee SH; Walshe M; Oh EH; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Greener T; Weizman AV; Silverberg MS; Ye BD
    Inflamm Bowel Dis; 2021 Aug; 27(9):1452-1461. PubMed ID: 33269403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.
    Guo A; Ross C; Chande N; Gregor J; Ponich T; Khanna R; Sey M; Beaton M; Yan B; Kim RB; Wilson A
    Sci Rep; 2022 Jan; 12(1):1185. PubMed ID: 35075155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis.
    Yoshida A; Matsuoka K; Ueno F; Morizane T; Endo Y; Hibi T
    Inflamm Intest Dis; 2021 May; 6(2):117-122. PubMed ID: 34124183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
    Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
    J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease.
    Song JH; Hong SN; Lee JE; Kim K; Kim TJ; Kim ER; Chang DK; Kim YH
    Scand J Gastroenterol; 2019 Jul; 54(7):876-885. PubMed ID: 31303093
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.
    Burke KE; Khalili H; Garber JJ; Haritunians T; McGovern DPB; Xavier RJ; Ananthakrishnan AN
    Inflamm Bowel Dis; 2018 Jul; 24(8):1840-1848. PubMed ID: 29718226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatments of inflammatory bowel disease toward personalized medicine.
    Kim KU; Kim J; Kim WH; Min H; Choi CH
    Arch Pharm Res; 2021 Mar; 44(3):293-309. PubMed ID: 33763844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
    BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
    Hiroz P; Vavricka SR; Fournier N; Safroneeva E; Pittet V; Rogler G; Schoepfer AM;
    Scand J Gastroenterol; 2014 Oct; 49(10):1207-18. PubMed ID: 25120029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
    Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort.
    Ezirike Ladipo J; He Z; Chikwava K; Robbins K; Beri J; Molle-Rios Z
    J Pediatr Gastroenterol Nutr; 2021 Sep; 73(3):352-357. PubMed ID: 34117193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review.
    Wang LF; Chen PR; He SK; Duan SH; Zhang Y
    World J Gastroenterol; 2023 Aug; 29(29):4481-4498. PubMed ID: 37621757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.
    Song JH; Kang EA; Park SK; Hong SN; Kim YS; Bang KB; Kim KO; Lee HS; Kang SB; Shin SY; Song EM; Im JP; Choi CH;
    Gut Liver; 2021 Sep; 15(5):752-762. PubMed ID: 33767028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment.
    Wen N; Zhao N; Xu H; Zhao Y; Ma J
    Ir J Med Sci; 2022 Oct; 191(5):2105-2111. PubMed ID: 34843071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.